ReviewClinical neuroradiology2015
MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update.
Review in Clinical neuroradiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 105 citations in OpenAlex.
- High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS.Neurology(R) neuroimmunology & neuroinflammation · 2019Trial
- Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients.Journal of neurology · 2017Trial
- Synthetic MRI and radiomics in multiple sclerosis: improving precision in diagnosis and prognosis.Radiological physics and technology · 2026Review
- A misdiagnosed case of tumefactive demyelinating lesion mimicking glioma: Imaging pitfalls and diagnostic lessons.Radiology case reports · 2026Article
- Longitudinal visualization tools for advanced characterization of multiple sclerosis lesions using diffusion MRI and magnetization transfer imaging metrics.Brain structure & function · 2026Article
- Implementing the 2024 revision of the McDonald diagnostic criteria for multiple sclerosis in Germany: Practical considerations and consensus recommendations.Therapeutic advances in neurological disorders · 2026Review
- Spheres of uncertainty: A phenomenological inquiry into healthcare practice surrounding the care for people with relapsing-remitting multiple sclerosis.Qualitative research in medicine & healthcare · 2025Article
- Updates in Multiple Sclerosis Imaging.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Review
- Super-Resolution in Clinically Available Spinal Cord MRIs Enables Automated Atrophy Analysis.AJNR. American journal of neuroradiology · 2025Article
- Effectiveness of Ocrelizumab on Disease Progression and Disability Status in Multiple Sclerosis Patients: A Two-Year Prospective Cohort Study.Journal of clinical medicine · 2025Article
- Detection of Spinal Cord Multiple Sclerosis Lesions Using a 3D-PSIR Sequence at 1.5 T.Clinical neuroradiology · 2024Article
- Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.CNS drugs · 2024Review
- Article
- Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a.Journal of neurology · 2023Article
- Scanner agnostic large-scale evaluation of MS lesion delineation tool for clinical MRI.Frontiers in neuroscience · 2023Article
- Serum neurofilament light in MS: The first true blood-based biomarker?Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Review
- Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- [New MRI guidelines for multiple sclerosis].Der Radiologe · 2022Review
- Genetics and functional genomics of multiple sclerosis.Seminars in immunopathology · 2022Review
- [Neuropsychological and MRI diagnostics in secondary progressive multiple sclerosis].Der Nervenarzt · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Magnetic resonance imaging (MRI) is the most powerful tool for the early (differential) diagnosis of multiple sclerosis (MS) and has been part of the International Panel criteria (2001, 2005, 2010) for more than 10 years. The role of brain and spinal cord MRI in the diagnosis of MS is well established. New MR techniques and markers will further improve the diagnostic value in a research and clinical routine setting. In addition to diagnosis, MRI is widely used for prognostic evaluation as well as treatment efficacy and safety monitoring. This field has gained importance with the introduction of new MS therapeutics. Therefore, the scope of MRI-guided MS disease monitoring has been widened to include rigorous treatment monitoring aiming at "no evidence of disease activity (NEDA)". Next, safety monitoring of treated MS patients has become major concern to enable early detection of opportunistic infections such as progressive multifocal leukoencephalopathy (PML). Driven by these new developments, recently published expert panel guidelines stressed the need for standardized imaging protocols and targeted specialized imaging markers for MS diagnosis and disease monitoring. This review article aims to give an update on the role of MRI in the diagnosis and monitoring of MS with particular emphasis to treatment efficacy and safety, both in clinical practice and in research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.